Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT02289690
Title Dose Escalation and Double-blind Study of Veliparib in Combination With Carboplatin and Etoposide in Treatment-naive Extensive Stage Disease Small Cell Lung Cancer
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors AbbVie

lung small cell carcinoma


Carboplatin + Etoposide + Veliparib

Age Groups: adult
Covered Countries USA | CAN

No variant requirements are available.